Opaleye Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Opaleye Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,055,000	Closed	-$692K	–	47
2025 Q1	$692K	Buy	+1,055,000	New	+$1.12M	0.15%	41
2019 Q1	–	Sell	-500,000	Closed	-$5.74M	–	59
2018 Q4	$5.74M	Buy	500,000 +10,000	+2%	+$124K	2.14%	16
2018 Q3	$8.3M	Sell	490,000 -15,000	-3%	-$228K	2.11%	16
2018 Q2	$7.17M	Sell	505,000 -30,000	-6%	-$498K	1.86%	19
2018 Q1	$10.2M	Sell	535,000 -45,000	-8%	-$962K	2.91%	10
2017 Q4	$9.51M	Hold	580,000	–	–	3.05%	10
2017 Q3	$8.7M	Hold	580,000	–	–	3.08%	9
2017 Q2	$5.1M	Sell	580,000 -1,000	-0.2%	-$6.42K	2.13%	16
2017 Q1	$3.02M	Buy	581,000 +181,000	+45%	+$726K	1.5%	23
2016 Q4	$1.22M	Buy	+400,000	New	+$1.46M	0.72%	34
2016 Q1	–	Sell	-60,000	Closed	-$548K	–	58
2015 Q4	$548K	Buy	+60,000	New	+$462K	0.23%	51

Other funds holding SGMO

YAG

Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Opaleye Management's SGMO Position: Q2 2025 in Review

Opaleye Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2025, closing a stake of 1,055,000 shares — an estimated $692K sold.

Opaleye Management first reported a position in SGMO in Q4 2015 and held it in 11 quarters. The position peaked at $10.2M in Q1 2018. 114 funds tracked by Wall St. Rank hold SGMO as of Q2 2025.

Opaleye Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
Opaleye Management sold 1,055,000 SANGAMO THERAPEUTICS INC shares in Q2 2025, an estimated $692K.
Opaleye Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2015 and held it in 11 quarters.
Opaleye Management's SANGAMO THERAPEUTICS INC position peaked at $10.2M in Q1 2018.
114 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2025.

Based on Opaleye Management's 13F filing for Q2 2025, filed 14 Aug 2025.